The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Open accessAbstract
BACKGROUND: Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential effects of that drug. METHODS: We sequenced the exons of NPC1L1 in 7364 patients with coronary heart disease and in 14,728 controls without such disease who were of European, African, or South Asian ancestry. We identified carriers of inactivating mutations (nonsense, splice-site, or frameshift mutations). In addition, we genotyped a specific inactivating mutation (p.Arg406X) in 22,590 patients with coronary heart disease and in 68,412 controls. We tested the association between the presence of an inactivating mutation and both plasma lipid levels and the risk of coronary heart disease. RESULTS: With sequencing, we identified 15 distinct NPC1L1 inactivating mutations; approximately 1 in every 650 persons was a heterozygous carrier for 1 of these mutations. Heterozygous carriers of NPC1L1 inactivating mutations had a mean LDL cholesterol level that was 12 mg per deciliter (0.31 mmol per liter) lower than that in noncarriers (P=0.04). Carrier status was associated with a relative reduction of 53% in the risk of coronary heart disease (odds ratio for carriers, 0.47; 95% confidence interval, 0.25 to 0.87; P=0.008). In total, only 11 of 29,954 patients with coronary heart disease had an inactivating mutation (carrier frequency, 0.04%) in contrast to 71 of 83,140 controls (carrier frequency, 0.09%). CONCLUSIONS: Naturally occurring mutations that disrupt NPC1L1 function were found to be associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A genetic sequencing study involving more than 90,000 patients found significantly lower LDL-C levels and a lower risk of coronary heart diseases among patients with NPC1L1 mutations [58]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Polymorphisms affecting NPC1L1 are associated with both lower levels of LDL cholesterol and a lower risk of cardiovascular events.19”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“There is no clear evidence that statins have a clinically significant beneficial or adverse effect on renal function [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“A systematic review of the benefits and harms of statins in patients with a functioning kidney transplant included 3465 patients, free of CHD, from 22 studies. Although the authors concluded that statins may reduce CV events, they also suggested a need for additional studies [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“A systematic review of the benefits and harms of statins in patients with a functioning kidney transplant included 3465 patients, free of CHD, from 22 studies. Although the authors concluded that statins may reduce CV events, they also suggested a need for additional studies [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“Naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [245]
In the citing paper
“Similarly, a lifelong reduction of only 11% in plasma LDL-cholesterol levels due to loss-of-function mutations in NPC1L1, an intestinal cholesterol transporter, causes a striking 53% reduction in myocardial infarction (37).”
From Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms (2018) · cites this paper as [37]
In the citing paper
“Naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.245”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [245]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
(1989) · PubMed · Cited by 3,139
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G. G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,818
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J. R., Kwiterovich, P. O., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,645
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Krawczak, M., Reiss, J., & Cooper, D. N. (1992) · Human Genetics · doi:10.1007/bf00210743 · Cited by 1,344
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Guidelines for investigating causality of sequence variants in human disease
MacArthur, D. G., Manolio, T. A., Dimmock, D. P., Rehm, H. L., Shendure, J., Abecasis, G. R., Adams, D. R., Altman, R. B., Antonarakis, S. E., Ashley, E. A., et al. (2014) · Nature · doi:10.1038/nature13127 · Cited by 1,224
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine
Roden, D. M., Pulley, J. M., Basford, M., Bernard, G. R., Clayton, E. W., Balser, J., & Masys, D. R. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.89 · Cited by 966
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
Garcia-Calvo, M., Lisnock, J., Bull, H. G., Hawes, B. E., Burnett, D. A., Braun, M. P., Crona, J. H., Davis, H. R., Dean, D. C., Detmers, P. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500269102 · Cited by 670
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650
Searching for missing heritability: Designing rare variant association studies
Zuk, O., Schaffner, S. F., Samocha, K., Do, R., Hechter, E., Kathiresan, S., Daly, M. J., Neale, B. M., Sunyaev, S. R., & Lander, E. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322563111 · Cited by 635
Davis, H. R., Zhu, L.-J., Hoos, L. M., Tetzloff, G., Maguire, M., Liu, J., Yao, X., Iyer, S. P. N., Lam, M.-H., Lund, E. G., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405817200 · Cited by 615
A Common Allele on Chromosome 9 Associated With Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A. F. R., Roberts, R., Cox, D., Hinds, D. A., Pennacchio, L. A., Tybjærg‐Hansen, A., Folsom, A. R., et al. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000279314.45442.bb · Cited by 524
Cohen, J. C., Pertsemlidis, A., Fahmi, S., Esmail, S., Vega, G. L., Grundy, S. M., & Hobbs, H. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508483103 · Cited by 380
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J. T., Musliner, T. A., McCabe, C. H., Veltri, E. P., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 294
Dysfunctional nitric oxide signalling increases risk of myocardial infarction
CARDIoGRAM, Erdmann, J., Stark, K. J., Esslinger, U. B., Rumpf, P. M., Koesling, D., de Wit, C., Kaiser, F. J., Braunholz, D., Medack, A., et al. (2013) · Nature · doi:10.1038/nature12722 · Cited by 287
Curses—Winner's and Otherwise—in Genetic Epidemiology
Kraft, P. L. (2008) · Epidemiology · doi:10.1097/ede.0b013e318181b865 · Cited by 222
NPC1L1 and cholesterol transport
Betters, J. L., & Yu, L. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.03.030 · Cited by 213
zCall: a rare variant caller for array-based genotyping
Goldstein, J. I., Crenshaw, A., Carey, J., Grant, G. B., Maguire, J., Fromer, M., O’Dushlaine, C., Moran, J. L., Chambert, K., Stevens, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts479 · Cited by 196
Atherosclerosis, T. (2003) · Circulation · doi:10.1161/01.cir.0000051465.94572.d0 · Cited by 193
The Jackson Heart Study: an overview.
Taylor, H. A. (2005) · PubMed · Cited by 182
Ridker, P. M., Chasman, D. I., Zee, R. Y. L., Parker, A. N., Rose, L. M., Cook, N. R., Buring, J. E., & for the Women’s Genome Health Study Working Group (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.099366 · Cited by 169
Hegele, R. A., Guy, J., Ban, M. R., & Wang, J. (2005) · Lipids in Health and Disease · doi:10.1186/1476-511x-4-16 · Cited by 129
Saleheen, D., Zaidi, M. A., Rasheed, A., Ahmad, U., Hakeem, A., Murtaza, M., Kayani, W. T., FARUQUI, A. M. A., Kundi, A., Zaman, K. S., et al. (2009) · European Journal of Epidemiology · doi:10.1007/s10654-009-9334-y · Cited by 105
Cardiovascular Risk in Type 2 Diabetes Is Associated With Variation at the PPARG Locus
Doney, A. S. F., Fischer, B., Leese, G., Morris, A. D., & Palmer, C. N. A. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000147897.57527.e4 · Cited by 82
Wang, J., Williams, C., & Hegele, R. (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00388.x · Cited by 68
The Plasma Concentration and LDL-C Relationship in Patients Receiving Ezetimibe
Ezzet, F., Wexler, D. B., Statkevich, P., Kosoglou, T., Patrick, J. E., Lipka, L., Mellars, L., Veltri, E. P., & Batra, V. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010915 · Cited by 59
Fahmi, S., Yang, C., Esmail, S., Hobbs, H. H., & Cohen, J. C. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn108 · Cited by 59
Sentı́, M., Tomás, M., Marrugat, J., & Elosúa, R. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.415 · Cited by 51
APOC3, Coronary Disease, and Complexities of Mendelian Randomization
Cohen, J. C., Stender, S., & Hobbs, H. H. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.007 · Cited by 45
Ye, Z., Kalloo, F. S., Dalenberg, A. K., & Kullo, I. J. (2013) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2013.10 · Cited by 23
Emphasizing the Burden of Proof
Krumholz, H. M. (2010) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959577 · Cited by 11
Flagged first, then by citations
Research works printed but not linked: 2
- Taylor HA, 2005, Ethn Dis, 15, S6
- Ye Z, 2013, Glob Cardiol Sci Pract, 2013, 82
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Next-generation genotype imputation service and methods
Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A., Vrieze, S. I., Chew, E. Y., Levy, S., McGue, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3656 · Cited by 3,808
Metadata
- Authors
- The Myocardial Infarction Genetics Consortium Investigators
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- The Myocardial Infarction Genetics Consortium Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-27
- Volume
- 371
- Issue
- 22
- Pages
- 2072-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4335708
- OpenAlex
- W2478496979
- Cited by
- 419
- References
- 41
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 13 · 2023: 21 · 2022: 19 · 2021: 26 · 2020: 36 · 2019: 44 · 2018: 31 · 2017: 47 · 2016: 84 · 2015: 73 · 2014: 5
- FWCI
- 69.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- National Institutes of Health (UL1TR000124)
- Canadian Institutes of Health Research
- Medical Research Council (MR/L003120/1)
- National Institute on Aging (U01AG049505)
- National Heart, Lung, and Blood Institute (RC2HL102925, K08HL114642, RC2HL102926, R01HL107816, T32HL007208)
- National Human Genome Research Institute (U54HG003067, U01HG006378)
- National Cancer Institute (R01CA082659)
- National Institute of Nursing Research (R01NR013396)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK063491)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- NPC1L1, loss-of-function mutations, coronary artery disease, ezetimibe, LDL cholesterol, plasma lipids, genetic variants, therapeutic target, LDL cholesterol lowering
- MeSH terms
- Adult, Coronary Disease, Exons, Female, Genotype, Humans, Cholesterol, LDL, Male, Membrane Proteins, Middle Aged, Mutation, Protein Conformation, Risk, Triglycerides, Case-Control Studies, Sequence Analysis, DNA, Gene Silencing, Membrane Transport Proteins, Black People, White People, Asian People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
